[The importance of the pharmaceutical form and the routes of administration of B-group vitamins for the efficacious treatment of neurosensorial hearing loss].
The objective of the present comparative study was to estimate the efficacy of the treatment of neurosensorial hearing loss (NSHL) with the use of milgamma, milgamma compositum, and vitamins B1 and B2 monotherapy. The best results were obtained after the treatment with milgamma and milgamma compositum. It is concluded that the use of these preparations for the combined treatment of neurosensorial hearing loss is pathogenetically justified since it permits to achieve the improvement of the functional state of the cochleovestibular nerve and the enhancement of patient compliance; moreover, it reduces the work load on the medical personnel.
V F
VF
Antoniv
K V
KV
Efimochkina
T V
TV
Antoniv
V I
VI
Popadiuk
A U
AU
Kakupshev
D000328:Adult; D001702:Biopharmaceutics; D003056:Cochlear Nerve / Q000502:physiology*; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009416:Nerve Regeneration / Q000187:drug effects; D012256:Riboflavin / Q000008:administration & dosage*; D013831:Thiamine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016896:Treatment Outcome; D014803:Vitamin B Complex / Q000008:administration & dosage*
D014803:Vitamin B Complex; D012256:Riboflavin; D013831:Thiamine; C013835:benphothiamine